Evidence map›Paper›PMID 42751545›Full record

ArticleImmunotherapy advances2026

L-Arginine supplementation improves the survival of virus-specific CD8

Takahiro Tomoda, Ai Kawana-Tachikawa, Shigeomi Shimizu, Satoshi Takahashi, Hirokazu Kanegane, Takahiro Kamiya, Kumi Inoue, Masatoshi Takagi, Tomohiro Morio

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Takahiro TomodaDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo, Japan.ORCID https://orcid.org/0009-0004-9145-2869
Ai Kawana-TachikawaAIDS Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Shigeomi ShimizuDepartment of Pathological Cell Biology, Institute of Science Tokyo, Tokyo, Japan.
Satoshi TakahashiDivision of Clinical Precision Research Platform, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Hirokazu KaneganeDepartment of Child Health and Development, Institute of Science Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-8696-9378
Takahiro KamiyaDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo, Japan.
Kumi InoueLaboratory of Immunology and Molecular Medicine, Advanced Research Initiative, Institute of Science Tokyo, Tokyo, Japan.
Masatoshi TakagiDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo, Japan.
Tomohiro MorioLaboratory of Immunology and Molecular Medicine, Advanced Research Initiative, Institute of Science Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-9259-1025

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Virus-specific T cell therapy is a promising treatment for life-threatening viral infections following allogeneic hematopoietic stem cell transplantation. However, its efficacy is limited by apoptotic cell loss during Materials and methods: Human virus-specific T cells were expanded Results: Supplementation of the culture medium with L-arginine enhanced the survival of human virus-specific T cells during Conclusion: Together, these findings support L-arginine supplementation as a simple and clinically applicable strategy to enhance the durability of virus-specific T cell products during

Indexed as

apoptosiscytokine signalingL-arginineMCL-1virus-specific T-cell therapy

Identifiers

PMID42751545
PMCPMC13580084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.